(Q41660033)

6 October 2017

title

MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells (English)

1 reference

6 October 2017

1 reference

J Cui

1

1 reference

6 October 2017

Y Yang

2

1 reference

6 October 2017

H Li

3

1 reference

6 October 2017

Y Leng

4

1 reference

6 October 2017

K Qian

5

1 reference

6 October 2017

Q Huang

6

1 reference

6 October 2017

C Zhang

7

1 reference

6 October 2017

Z Lu

8

1 reference

6 October 2017

J Chen

9

1 reference

6 October 2017

T Sun

10

1 reference

6 October 2017

R Wu

11

1 reference

6 October 2017

Y Sun

12

1 reference

6 October 2017

H Song

13

1 reference

6 October 2017

X Wei

14

1 reference

6 October 2017

P Jing

15

1 reference

6 October 2017

X Yang

16

1 reference

6 October 2017

C Zhang

17

1 reference

6 October 2017

language of work or name

English

0 references

publication date

22 December 2014

1 reference

6 October 2017

1 reference

6 October 2017

volume

34

1 reference

6 October 2017

issue

30

1 reference

6 October 2017

page(s)

3895-3907

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2014.430

6 October 2017

exact match

0 references

cites work

Estrogen and the risk of breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Estrogen carcinogenesis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

The different roles of ER subtypes in cancer biology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Estrogen receptor interaction with estrogen response elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Molecular basis of agonism and antagonism in the oestrogen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Molecular determinants for the tissue specificity of SERMs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Derailed estrogen signaling and breast cancer: an authentic couple.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Development of subtype-selective oestrogen receptor-based therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Endocrine-responsive breast cancer and strategies for combating resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Mechanisms of endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

miRNA dysregulation in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Clinical applications for microRNAs in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

The shaping and functional consequences of the microRNA landscape in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

miRNAs and estrogen action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Genome-wide profiling of chromatin signatures reveals epigenetic regulation of MicroRNA genes in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Cyclin-dependent kinase 3-mediated activating transcription factor 1 phosphorylation enhances cell transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

MicroRNAs and cancer stem cells: the sword and the shield

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

A role for estrogen receptor phosphorylation in the resistance to tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyper-response to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Cyclin C/cdk3 promotes Rb-dependent G0 exit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

The CDK inhibitors in cancer research and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

A premature-termination mutation in the Mus musculus cyclin-dependent kinase 3 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Arginine and glutamate-rich 1 (ARGLU1) interacts with mediator subunit 1 (MED1) and is required for estrogen receptor-mediated gene transcription and breast cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

FBI-1 functions as a novel AR co-repressor in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Cyclin-dependent kinase-3-mediated c-Jun phosphorylation at Ser63 and Ser73 enhances cell transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

CDK3 expression and its clinical significance in human nasopharyngeal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2014.430

Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25531331

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25531331

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/ONC.2014.430

1 reference

Dimensions Publication ID

6 October 2017

1033351931

0 references

Fatcat ID

release_b5f2tsxy5reepijdi56u2f6te4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/b5f2tsxy5reepijdi56u2f6te4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference